Cargando…

2743. Safety of Recombinant Influenza Vaccine Compared with Inactivated Influenza Vaccine in Adults

BACKGROUND: In 2013, a recombinant trivalent influenza vaccine (RIV, Flublok®, Sanofi Pasteur) was licensed for use against influenza virus subtypes A and B contained in the vaccine for persons 18–49 years of age and approved for all adults ≥18 years of age in 2014. The study aim was to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hansen, John, Goddard, Kristin, Timbol, Julius, Zhang, Lea, Lewis, Ned, Klein, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810428/ http://dx.doi.org/10.1093/ofid/ofz360.2420

Ejemplares similares

Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study
por: Hansen, John, et al.
Publicado: (2020)

2322. Effectiveness of Recombinant Influenza Vaccine vs. Standard Dose Inactivated Influenza Vaccines Against Hospitalized Influenza-Related Outcomes in Adults: A Cluster Randomized Trial
por: Hsiao, Amber, et al.
Publicado: (2022)

LB15. Vaccine Effectiveness of Flucelvax Relative to Inactivated Influenza Vaccine During the 2017–18 Influenza Season in Northern California
por: Klein, Nicola P, et al.
Publicado: (2018)

Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season
por: Klein, Nicola P., et al.
Publicado: (2020)

1059 Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults
por: Diazgranados, Carlos, et al.
Publicado: (2014)

Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines
por: Sridhar, Saranya, et al.
Publicado: (2015)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

1162. Influenza Vaccination Among Pregnant People in the Vaccine Safety Datalink, 2016-17 through 2022-23 Influenza Seasons
por: Irving, Stephanie, et al.
Publicado: (2023)

Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine
por: Hsiao, Amber, et al.
Publicado: (2022)

2766. Identification and Description of Mumps Cases in a Non-Outbreak Setting and Evaluation of the Effectiveness of Mumps Containing Vaccines Over Time
por: Zerbo, Ousseny, et al.
Publicado: (2019)

2275. Parental Risk Factors for Fever in their Children 7–10 Days After the First Dose of Measles-Containing Vaccines
por: Zerbo, Ousseny, et al.
Publicado: (2018)

Safety of Influenza Vaccination Among Hospitalized Patients
por: Tartof, Sara, et al.
Publicado: (2017)

1163. Influenza Vaccination Coverage through December among Persons Ages Six Months and Older in the Vaccine Safety Datalink, 2017-18 through 2022-23 Influenza Seasons
por: Irving, Stephanie, et al.
Publicado: (2023)

Recombinant Influenza Vaccines
por: Sedova, E.S., et al.
Publicado: (2012)

Influenza vaccination in pediatric age
por: Esposito, Susanna, et al.
Publicado: (2015)

Evaluation of concurrent vaccinations with recombinant canarypox equine influenza virus and inactivated equine herpesvirus vaccines
por: Lee, Dong-Ha, et al.
Publicado: (2022)

Serums and Vaccines in Influenza
Publicado: (1919)

177. Safety of Measles and Pertussis-containing Vaccines in School-age Children Previously Diagnosed with Autism Spectrum Disorders
por: Zerbo, Ousseny, et al.
Publicado: (2020)

2649. Measles-Containing Vaccination Resulted in a Balanced Cytokine Profile Without Evidence of Immunosuppression in Healthy 12-Month-Old Children
por: Gans, Hayley, et al.
Publicado: (2019)

990. Impact of Influenza Vaccination Setting on Timing of Vaccination in a National Sample of Influenza-Vaccinated Adults
por: Luther, Megan
Publicado: (2018)

High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors
por: Becker, Debbie L., et al.
Publicado: (2016)

Recombinant Vectors as Influenza Vaccines
por: Kopecky-Bromberg, Sarah A., et al.
Publicado: (2009)

Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15
por: Donahue, James G., et al.
Publicado: (2019)

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children
por: Nolan, Terry, et al.
Publicado: (2009)

Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production
por: Herrera-Rodriguez, José, et al.
Publicado: (2019)

Influenza Vaccination and Mortality: Differentiating Vaccine Effects From Bias
por: Fireman, Bruce, et al.
Publicado: (2009)

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
por: Liu, Xiaoqiang, et al.
Publicado: (2022)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
por: Hu, Yuemei, et al.
Publicado: (2019)

Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study
por: Simpson, Colin R, et al.
Publicado: (2017)

The Pregnancy Vaccine Effectiveness Network (PREVENT): Establishing a Multi-Country Cohort to Estimate Vaccine Effectiveness (VE) against Hospitalized Influenza During Pregnancy
por: Ball, Sarah, et al.
Publicado: (2017)

2743. Pre-Transplant Human T-Lymphotropic Virus Screening In Allogeneic Hematopoietic Stem Cell Transplant Recipients At A Large Metropolitan Tertiary Referral Centre In Melbourne, Australia
por: Paykin, Gabriel, et al.
Publicado: (2023)

LB20. Impact of School-Located Influenza Vaccination on Vaccination Coverage, School Absenteeism, and Influenza Hospitalization
por: Benjamin-Chung, Jade
Publicado: (2018)

Live Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma: A 14-year Follow-up Study
por: Baxter, Roger P., et al.
Publicado: (2018)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review
por: Giles, Michelle L., et al.
Publicado: (2018)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Safety of Inactivated Influenza Vaccine in Patients with Egg Allergy in Kurdistan Province, Iran
por: TOZANDEHJANI, Sima, et al.
Publicado: (2019)

29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season
por: Postma, Maarten, et al.
Publicado: (2020)

2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine
por: Tasker, Sybil, et al.
Publicado: (2018)

2481. Impact of Sex and Race/Ethnicity on the Effectiveness of Live Zoster Vaccine
por: Marks, Morgan A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kc5hhbkr6rhbk7m8fifqcqesmj